Pārskats
Akcijas cenas izmaiņa
24h
Šī brīža
Min
1.5899999999999999
Max
1.6800000000000002
Ienākumi | -45M -67M |
|---|---|
Pārdošana | -1.6M 33M |
EPS | -2.32 |
Peļņas marža | -200.476 |
Darbinieki | 228 |
EBITDA | -44M -54M |
Nākamie ieņēmumi | 2026. g. 2. nov. |
|---|
Tirgus kapitalizācija | -3.8M 41M |
|---|---|
Iepriekšējā atvēršanas cena | 8.94 |
Iepriekšējā slēgšanas cena | 1.49 |
Ziņu noskaņojums
By Acuity
50%
50%
144 / 339 Rangs Healthcare
Karyopharm Therapeutics Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
2026. g. 8. sept. 20:07 UTC
Karyopharm Therapeutics shares are lower after downgrades from Robert W. Baird and HC Wainwright, with a target price set at $3.00.
Lasīt
2026. g. 2. sept. 20:08 UTC
Karyopharm Therapeutics Inc shares are lower today, having reached a session low earlier. The stock remains near the lower end of its one-month range.
Lasīt
2026. g. 1. sept. 20:01 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, but shares are trading lower amid broader market concerns about rising oil prices and interest rates.
Lasīt
2026. g. 31. aug. 20:02 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application for XPOVIO, seeking Accelerated Approval for myelofibrosis treatment. Shares are gaining during Monday's session.
Lasīt
2026. g. 28. aug. 20:08 UTC
Karyopharm Therapeutics Inc shares declined during Friday's session amid rising U.S. Treasury yields, reflecting broader market trends. The stock finished near its one-month low.
Lasīt
2026. g. 25. aug. 20:07 UTC
Karyopharm Therapeutics Inc shares are higher during Tuesday's session, reaching a peak earlier in the day. The stock remains below its 20-day moving average.
Lasīt
2026. g. 24. aug. 19:16 UTC
Karyopharm Therapeutics Inc shares are lower today, reaching a session low amid ongoing market weakness and no specific news to explain the decline.
Lasīt
2026. g. 21. aug. 23:51 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.
Lasīt
2026. g. 20. aug. 20:02 UTC
Karyopharm Therapeutics is declining sharply amid a significant downturn in the Biotechnology sub-sector, nearing the lower end of its one-month trading range.
Lasīt
2026. g. 18. aug. 20:03 UTC
Karyopharm Therapeutics Inc is trading higher today, continuing its upward trend since Monday's close. The stock remains below its 20-day moving average.
Lasīt
2026. g. 17. aug. 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market hours, following volatility earlier. Broader market pressures include geopolitical tensions and rising crude oil prices.
Lasīt
2026. g. 14. aug. 23:51 UTC
Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.
Lasīt
2026. g. 13. aug. 23:11 UTC
Karyopharm Therapeutics Inc shares are rising in after-market trading, showing a modest upward trend since Thursday's close despite recent significant declines.
Lasīt
2026. g. 12. aug. 19:56 UTC
Karyopharm Therapeutics Inc shares are lower today, retracing from an early high amid broader market conditions and geopolitical tensions. No specific news was identified.
Lasīt
2026. g. 11. aug. 20:01 UTC
Karyopharm Therapeutics Inc is trading higher today, having reached a peak earlier in the session. The stock remains below its 20-day moving average.
Lasīt
2026. g. 10. aug. 20:06 UTC
Karyopharm Therapeutics Inc shares are lower today, reversing an early gain and reaching a mid-morning low, with no specific news identified for the decline.
Lasīt
2026. g. 7. aug. 23:31 UTC
Karyopharm Therapeutics shares are lower in after-market hours, following a decline earlier despite gains in major tech stocks. No specific news was identified.
Lasīt
2026. g. 6. aug. 23:21 UTC
Karyopharm Therapeutics Inc shares are lower in after-market hours. The asset is trading below its 20-day moving average and near the lower end of its one-month range.
Lasīt
2026. g. 5. aug. 23:01 UTC
Karyopharm Therapeutics shares are lower in after-market hours, continuing a three-session decline amid broader market weakness from disappointing U.S. employment data.
Lasīt
2026. g. 4. aug. 23:46 UTC
Karyopharm Therapeutics shares are higher in after-market trading, though no specific news explains the movement. Broader market optimism may be influencing risk assets.
Lasīt
2026. g. 3. aug. 23:41 UTC
Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.
Lasīt
2026. g. 1. aug. 00:01 UTC
Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.
Lasīt
2026. g. 31. jūl. 23:31 UTC
Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.
Lasīt
2026. g. 30. jūl. 23:41 UTC
Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.
Lasīt
2026. g. 29. jūl. 19:27 UTC
Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.
Lasīt
2026. g. 27. jūl. 19:07 UTC
Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.
Lasīt
2026. g. 24. jūl. 19:42 UTC
Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.
Lasīt
2026. g. 23. jūl. 09:01 UTC
Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.
Lasīt
2026. g. 22. jūl. 18:41 UTC
Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.
Lasīt
2026. g. 21. jūl. 20:12 UTC
Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.
Lasīt
Salīdzinājums
Cenas izmaiņa
Karyopharm Therapeutics Inc Prognoze
Vērtējuma vienprātība
By TipRanks
Mērens pirkt
6 ratings
4
Pirkt
2
Turēt
0
Pārdot
Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Karyopharm Therapeutics Inc — pēdējo 3 mēnešu laikā.
Noskaņojums
By Acuity
Ziņu noskaņojums
Neutral
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Zem vidējā
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$